Sort   by:  
 Page size 
TranscriptomicsMethylation profiling of Low-Risk Myelodysplastic Syndromes (MDSs)
Genome-wide expression and methylation profiling identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes (MDSs). Gene expression profiling signatures may be used to classify the subtypes of Myelodysplastic syndrome (MDS) patients. However,...
ORGANISM(S): Homo sapiens 
2012-09-28 | E-GEOD-41215 | biostudies-arrayexpress
TranscriptomicsExpression data of Low-Risk Myelodysplastic Syndromes (MDSs)
Genome-wide expression and methylation profiling identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes (MDSs). Gene expression profiling signatures may be used to classify the subtypes of Myelodysplastic syndrome (MDS) patients. However,...
ORGANISM(S): Homo sapiens 
2012-09-25 | E-GEOD-41130 | biostudies-arrayexpress
UnknownAntibody Response in Healthcare Workers During the SARS-CoV-2 Gamma Variant Outbreak in Manaus, Brazil.
Not available
S-EPMC12448572 | biostudies-literature
UnknownIncidence of and Risk Factors for SARS-CoV-2 Infection Among Vaccinated Healthcare Workers During Emergence of SARS-CoV-2 Gamma Variant in the Amazon Region, Brazil, 2021.
Not available
S-EPMC12497958 | biostudies-literature
UnknownPerioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.
Not available
S-EPMC12353838 | biostudies-literature
TranscriptomicsMesenchymal stem cells from myelodysplastic syndromes are functionally and genomically abnormal
Myelodysplastic syndromes (MDS) are a group of clonal disorders of hematopoietic stem cells. Mesenchymal stem cells (MSC) are the progenitors of the Bone Marrow (BM) stroma and have been involved in the physiopathology of MDS. The presence of cytogenetic aberrations on MSC from MDS patients is contr...
ORGANISM(S): Homo sapiens 
2010-05-25 | E-GEOD-10822 | biostudies-arrayexpress
UnknownBIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Not available
S-EPMC4671004 | biostudies-literature
UnknownColorectal Air-Liquid Interface Organoids Preserve Tumour-Immune Architecture and Reveal Local Treg Expansion After PD-1 Blockade.
Not available
S-EPMC12784706 | biostudies-literature
UnknownFirst-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
Not available
S-EPMC9896179 | biostudies-literature
UnknownMolecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry.
Not available
S-EPMC9923191 | biostudies-literature
Sort   by:  
 Page size